Pfizer invested $350 million to upgrade its Irish plant

On November 2nd Pfizer announced that it would invest $350m to upgrade three production sites in Ireland: Grange Castle in Dublin, Newbridge in Kildale and Ringaskiddy in Cork, which are expected to add about 300 jobs over the next two to three years.While COVID-19 is currently raging around the world, that hasn't stopped the New York-based centennity drugmaker from investing a lot.The investment is reportedly being used primarily to expand capacity and upgrade laboratory conditions, as well as to ensure that Pfizer can support the next wave of medical innovation in new technologies to transform production lines and equipment. The three plants in Ireland mainly produce medicines and vaccines, mainly in the areas of arthritis, inflammation, cancer, anti-infection, haemophilia, pain and stroke.Ringaskiddy, in County Cork, is Pfizer's first plant in Ireland and is currently being remodeled with the creation of a new drug development division to produce drug candidates for clinical trials. This shift is a very important development as it extends Pfizer's role in Ireland from producing approved drugs to supporting the early stages of the development of new drugs.Pfizer is currently in the eye for working with German partner BioNTech to develop the COVID-19 vaccine. The mRNA candidate vaccine, BNT162b2, is one of four current phase III efficacy trials in the United States. RELATED: New Crown Vaccine Research and Development Upgrades! Preliminary efficacy data from five drug companies, Pfizer, AZ and Johnson and Johnson, are expected to be completed as early as October, but have not yet been approved. However, at the FDA's request, safety data for two months will continue to be counted from half of the trial participants after the last injection. As a result, a phased mid-term efficacy analysis is expected to be expected in the third week of November, according to Pfizer's current trial registration and dosing speed program.In July, Pfizer received orders of up to $1.95 billion from the U.S. government. Pfizer/BioNTech's new crown vaccine has received a major order from the U.S. government to provide 100 million doses of the vaccine after obtaining authorization for emergency use, and to continue to provide another 500 million doses. In Europe, the BNT162b2 injection is undergoing a rolling review by the European Medicines Agency, and Pfizer and BioNTech have agreed to provide 200 million doses of vaccination.To meet potential capacity planning, Pfizer has designated three U.S. plants and one Belgian plant as production sites for its COVID-19 vaccine.Currently, Grange Castle in Dublin is helping Belgian plants conduct mass production quality tests to ensure that production data is available before safety data for clinical trials are published to support COVID-19 vaccination and application in the United States.In addition, Pfizer's increased investment in its Irish plant comes amid plans to close its sterile injection site in Perth, Australia, and give a specific exit date to complete the business by 2023 and shift its relative functions to its Melbourne, Australia, and other overseas plants. (Sina Pharmaceutical News
): Pfizer to invest 300M, add 300 jobs to expand 3 Irish manufacturing sites